Maintain gastrointestinal (GI) comfort and healthy digestive function: Lactobacillus acidophilus (NCFM®) is one of the world’s most researched acidophilus strains and has been used exclusively in Metagenics probiotics for almost 30 years. Studies have shown benefits for patients experiencing digestive discomfort. For example, a 2014 clinical trial found a modulatory effect of colonic mucosal opioid receptor expression and activity in patients with functional abdominal pain at 20 billion CFU/day.¹ Further, a 2017 Australian randomised trial combining NCFM® and Bi-07 showed a significant reduction in the duration of pain post colonoscopy.²  SB is understood to support healthy GI function and has been shown to increase short chain fatty acid production.3 NCFM® is also able to maintain beneficial intestinal flora to help restore GI wellbeing.⁴

Regulation of transit time and flora balance: Bifidobacterium animalis ssp lactis (HN019™) has been clinically trialled in 2011, demonstrating a decrease in gut transit time at a daily dose of 1.8 billion CFU and a reduction in the frequency of functional GI symptoms.⁵ HN019 has also been researched in combination with NCFM® and HN001^®.^{6, 7} SB's effects have been shown to be dose dependent in a 2010 systematic review and meta-analysis, which included a study involving 3,000 subjects.³ For example, 5 billion CFU (250 mg) SB may be used to maintain gut health by preventing pathogenic attachment to intestinal receptors.³

Immune wellbeing: Lactobacillus rhamnosus (HN001™) is a well-researched probiotic with a wide body of evidence for immune wellbeing. A 2018 randomised, controlled trial shows a reduction in Staphylococcus aureus in the stool and the GI tract at a dose of 10 billion CFU per day.⁸ After four weeks, presence of S. aureus in the GI tract was reduced by 73%.⁸ HN019™ has been shown to help improve the body’s defence against infection through strengthening immune function and specific immune cell activity (phagocytes and natural killer cells).⁹